Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art

Vaccine

Volumn 33, Issue 39, 2015, Pages 5042-5050

  Toh, Zheng Quan ^a   Licciardi, Paul V ^a,b   Fong, James ^c   Garland, Suzanne M ^b,d   Tabrizi, Sepehr N ^b,d   Russell, Fiona M ^a,b   Mulholland, Edward K ^a,e,f  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Ministry of Health   (Fiji)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antibody response; Cervical cancer; HPV vaccines; Human papillomavirus; Long term protection; Reduced dose schedules

Indexed keywords

WART VIRUS VACCINE; BIOLOGICAL MARKER; VIRUS ANTIBODY;

ANTIBODY RESPONSE; COMPARATIVE STUDY; DRUG DOSE REGIMEN; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VACCINATION; WORLD HEALTH ORGANIZATION; ADOLESCENT; ADULT; ANUS NEOPLASMS; BLOOD; CHILD; CLINICAL TRIAL (TOPIC); COMPLICATION; ECONOMICS; FEMALE; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANUS NEOPLASMS; BIOMARKERS; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS; YOUNG ADULT;

EID: 84941742503     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.102     Document Type: Review

References (72)

1. Durst M., Gissmann L., Ikenberg H., zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983, 80(June (12)):3812-3815.
2. Munoz N., Bosch F.X., de Sanjose S., Tafur L., Izarzugaza I., Gili M., et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992, 52(November (5)):743-749.
3. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87(June (11)):796-802.
4. Schiller J.T., Hidesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 2000, 19(October (1-2)):67-74.
5. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(November (11)):1048-1056.
6. GLOBOCAN GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 2012, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [accessed 18.12.14].
7. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008, 109(May (2 Suppl)):S15-S21.
8. Molano M., Van den Brule A., Plummer M., Weiderpass E., Posso H., Arslan A., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158(September (5)):486-494.
9. Stanley M.A. Immune responses to human papilloma viruses. Indian J Med Res 2009, 130(September (3)):266-276.
10. Wright T.C., Ellerbrock T.V., Chiasson M.A., Van Devanter N., Sun X.W. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears, New York Cervical Disease Study. Obstet Gynecol 1994, 84(October (4)):591-597.
11. Fruchter R.G., Maiman M., Sedlis A., Bartley L., Camilien L., Arrastia C.D. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996, 87(March (3)):338-344.
12. Fennema J.S., van Ameijden E.J., Coutinho R.A., van den Hoek A.A. HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam. AIDS 1995, 9(September (9)):1071-1078.
13. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181(June (6)):1911-1919.
14. Kirnbauer R., Hubbert N.L., Wheeler C.M., Becker T.M., Lowy D.R., Schiller J.T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994, 86(April (7)):494-499.
15. World Health Organization WHO position on HPV vaccines. Vaccine 2009, 27(December (52)):7236-7237.
16. Garcon N., Wettendorff M., Van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011, 11(May (5)):667-677.
17. Merck & Co., Inc. Gardasil 9 prescribing information 2014, Available from: http://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf [accessed 24.02.15].
18. Joura E.A., Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015, 372(February (8)):711-723.
19. Future I/II Study Group, Dillner J., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493.
20. Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(May (19)):1915-1927.
21. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(May (19)):1928-1943.
22. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13(January (1)):89-99.
23. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(July (9686)):301-314.
24. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(November (9447)):1757-1765.
25. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006, 24(July (27-28)):5571-5583.
26. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95(December (11)):1459-1466.
27. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(April (9518)):1247-1255.
28. Rowhani-Rahbar A., Alvarez F.B., Bryan J.T., Hughes J.P., Hawes S.E., Weiss N.S., et al. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 2012, 53(March (3)):239-243.
29. Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., de Borba P.C., Sanchez N., et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccines Immunother 2014, 10(August (8)):2147-2162.
30. Ferris D., Samakoses R., Block S.L., Lazcano-Ponce E., Restrepo J.A., Reisinger K.S., et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 2014, 134(September (3)):e657-e665.
31. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(May (5)):271-278.
32. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118(November (5)):2135-2145.
33. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007, 40(June (6)):564-571.
34. Petaja T., Keranen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009, 44(January (1)):33-40.
35. Van Damme P., Olsson S.E., Block S., Castellsague X., Gray G.E., Herrera T., et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics 2015, 136(July (1)):e28-e39.
36. Russell F.M., Carapetis J.R., Burton R.L., Lin J., Licciardi P.V., Balloch A., et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 2011, 29(January (3)):535-544.
37. Raczniak G.A., Thomas T.K., Bulkow L.R., Negus S.E., Zanis C.L., Bruce M.G., et al. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine 2013, 31(April (17)):2152-2155.
38. National Advisory Committee on Immunization Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS). Canada Commun Dis Rep 2007, 33(November (ACS-11)):1-12.
39. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309(May (17)):1793-1802.
40. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(October (19)):1444-1451.
41. Lazcano-Ponce E., Stanley M., Munoz N., Torres L., Cruz-Valdez A., Salmeron J., et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014, 32(February (6)):725-732.
42. Romanowski B., Schwarz T.F., Ferguson L.M., Ferguson M., Peters K., Dionne M., et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccines Immunother 2014, 10(February (5)).
43. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccines 2011, 7(December (12)):1374-1386.
44. LaMontagne D.S., Mugisha E., Pan Y., Kumakech E., Ssemaganda A., Kemp T.J., et al. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda. Vaccine 2014, 32(October (47)):6303-6311.
45. Puthanakit T., Schwarz T., Esposito S., Frenette L., McNeil S., Rheault P., et al. Immune responses to a 2-dose schedule of the hpv-16/18 as04-adjuvanted vaccine in girls (9-14) versus 3 doses in women (15-25): a randomised trial. Eurogin 2013 International Multidisciplinary Congress 2013 2013, 1-5.
46. Kavanagh K., Pollock K.G., Potts A., Love J., Cuschieri K., Cubie H., et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014, 110(May (11)):2804-2811.
47. Gertig D.M., Brotherton J.M., Budd A.C., Drennan K., Chappell G., Saville A.M. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013, 11:227.
48. Crowe E., Pandeya N., Brotherton J.M., Dobson A.J., Kisely S., Lambert S.B., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014, 348:g1458.
49. Blomberg M., Dehlendorff C., Munk C., Kjaer S.K. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013, 57(October (7)):929-934.
50. Herweijer E., Leval A., Ploner A., Eloranta S., Simard J.F., Dillner J., et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014, 311(February (6)):597-603.
51. World Health Organization Human papillomavirus vaccines: WHO position paper, October 2014. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations 2014, 89(October (43)):465-491.
52. World Health Organization WHO weekly epidemiological record 2014, Available from: http://www.who.int/wer/2014/wer8921.pdf?ua=1 [accessed 25.08.14].
53. Donken R., Knol M.J., Bogaards J.A., van der Klis F.R., Meijer C.J., de Melker H.E. Inconclusive evidence for non-inferior immunogenicity of two-compared with three-dose HPV immunization schedules in preadolescent girls: a systematic review and meta-analysis. J Infect 2015, (February).
54. Safaeian M., Kemp T.J., Pan D.Y., Porras C., Rodriguez A.C., Schiffman M., et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccines Immunother 2013, 9(July (7)):1399-1406.
55. Barzon L., Squarzon L., Masiero S., Pacenti M., Marcati G., Mantelli B., et al. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine 2014, 32(September (41)):5357-5362.
56. Tabrizi S.N., Brotherton J.M., Kaldor J.M., Skinner S.R., Liu B., Bateson D., et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014, 14(October (10)):958-966.
57. Pons-Salort M., Thiebaut A.C., Guillemot D., Favre M., Delarocque-Astagneau E. HPV genotype replacement: too early to tell. Lancet Infect Dis 2013, 13(December (12)):1012.
58. Kahn J.A., Bernstein D.I. HPV vaccination: too soon for 2 doses?. JAMA 2013, 309(May (17)):1832-1834.
59. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9(March (3)):185-194.
60. Marais D., Passmore J.A., Maclean J., Rose R., Williamson A.L. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles. J Gen Virol 1999, 80(September (Pt 9)):2471-2475.
61. Siegrist C.A. Vaccine immunology. Vaccines 2008, 17-36. Elsevier, New York, USA. 5th ed. S.A. Plotkin WAO, P.A. Offit (Eds.).
62. Smolen K.K., Gelinas L., Franzen L., Dobson S., Dawar M., Ogilvie G., et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012, 30(May (24)):3572-3579.
63. Garcia-Pineres A.J., Hildesheim A., Dodd L., Kemp T.J., Yang J., Fullmer B., et al. Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol 2009, 182(February (3)):1706-1729.
64. Toh Z.Q., Licciardi P.V., Fong J., Tuivaga E., Bright K., Reyburn R., et al. HPV vaccination in Fiji: providing evidence for a reduced dose schedule. Fiji J Public Health 2014, 3(June (2)):14-16.
65. Inglis S., Shaw A., Koenig S. Chapter 11: HPV vaccines: commercial research & development. Vaccine. 2006, 24(August (Suppl 3:S3)):99-105.
66. Yang R., Murillo F.M., Delannoy M.J., Blosser R.L., Yutzy W.H., Uematsu S., et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005, 174(June (12)):7912-7919.
67. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res 2013, 6(November (11)):1242-1250.
68. Dupuy C., Buzoni-Gatel D., Touze A., Le Cann P., Bout D., Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microbial Pathog 1997, 22(April (4)):219-225.
69. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298(August (7)):743-753.
70. Pinto L.A., Castle P.E., Roden R.B., Harro C.D., Lowy D.R., Schiller J.T., et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 2005, 23(May (27)):3555-3564.
71. Dauner J.G., Pan Y., Hildesheim A., Harro C., Pinto L.A. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010, 28(July (33)):5407-5413.
72. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(August (33-34)):5937-5949.